论文部分内容阅读
目的:观察瑞格列奈治疗初发2型糖尿病的疗效。方法:对200例初发2型糖尿病患者在饮食控制及运动治疗基础上,给予瑞格列奈1 mg,每天3次,饭前服用,观察16周。分别于治疗8周及16周后测量体重指数、血脂、空腹血糖、餐后血糖、糖基化血红蛋白、空腹胰岛素水平。结果:治疗16周后患者的空腹血糖、餐后2 h血糖、糖基化血红蛋白水平均明显下降(P<0.01)。结论:瑞格列奈能有效控制2型糖尿病患者的血糖,不良反应少,且低血糖发生率低。
Objective: To observe the curative effect of repaglinide on newly diagnosed type 2 diabetes mellitus. Methods: 200 cases of newly diagnosed type 2 diabetic patients were given repaglinide 1 mg three times a day on the basis of diet control and exercise therapy. They were taken before meals and were observed for 16 weeks. Body mass index, blood lipid, fasting blood glucose, postprandial blood glucose, glycosylated hemoglobin and fasting insulin were measured at 8 and 16 weeks after treatment, respectively. Results: After 16 weeks of treatment, the fasting blood glucose, postprandial 2-h blood glucose and glycosylated hemoglobin were significantly decreased (P <0.01). Conclusion: Repaglinide is effective in controlling type 2 diabetes with low adverse reactions and low incidence of hypoglycemia.